|
Synonyms: Briumvi® | LFB-R603 | TG-1101 | TGTX-1101 | ublituximab-xiiy
ublituximab is an approved drug (FDA (2022), EMA (2023))
Compound class:
Antibody
Comment: Ublituximab is a novel third-generation anti-CD20 monoclonal antibody, CD20 being the B lymphocyte cell surface glycoprotein encoded by the MS4A1 gene. This chimeric antibody has been glycoengineered (namely, having a low fucose content in its Fc region) to optimise FcγRIIIA (CD16a) binding, to enhance antibody-dependent cell-mediated cytotoxicity [1-2]. It is being investigated for its immunomodulatory potential.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Ublituximab shows similar specificity and a similar glycosylation pattern to the anti-CD20 mAb EMAB-6 [1]. |
| Immunopharmacology Comments |
| Potential immunomodulatory activity. |
